Brief: Fusen Pharmaceutical Expects Loss Of RMB170 Million To RMB210 Million For FY
20/03/2025 17:27
March 20 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK: EXPECTED LOSS OF RMB170 MILLION TO RMB210 MILLION FOR FY2024 EXPECTED RESULT DUE TO CONTINUING INVESTMENT BY GROUP IN RESEARCH AND DEVELOPMENT IN FY, OTHERS Further company coverage: 1652.HK ((Reuters.Briefs@thomsonreuters.com))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA